|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||33.75 - 34.02|
|52 Week Range||26.30 - 34.02|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||22.16|
|Forward Dividend & Yield||1.09 (3.24%)|
|1y Target Est||34.03|
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
TOKYO—A new pill that can kill the flu virus in 24 hours with a single dose has become the most-prescribed influenza treatment in Japan, which is suffering through its worst flu season in two decades. The pill, called Xofluza, was discovered by Osaka-based Shionogi & Co. and it was approved last year by regulators in Japan and the U.S. In the U.S., it is marketed by Roche Holding AG’s Genentech unit. The drug quickly gained the top share in Japan, according to Shionogi’s data, in part because of its ease of use.
Trading data from OTC Markets Group shows that shares of government-sponsored entities Fannie Mae and Freddie Mac saw a dramatic increase in dollar trading volume last month. Common shares of Fannie Mae ...
This exciting area of cancer research could turn into a huge industry. How can investors potentially profit?
Macrogenics stock rocketed by triple digits Wednesday after the firm said its breast cancer treatment outperformed Roche's competing drug, the blockbuster Herceptin, in a late-stage study.
Roche and Bristol-Myers Squibb are most exposed among large-cap pharmaceuticals firms to Medicare Plan B sales, notes Credit Suisse.
Switzerland's Roche will donate its new hemophilia A drug Hemlibra to a World Hemophilia Federation program, it said on Wednesday, joining rivals who also back the effort to help patients in developing countries who face treatment hurdles. Roche's donation will focus on patients who have developed resistance, or inhibitors, to current hemophilia A treatments as well as children, the Basel-based company said in a statement. Roche joins other companies including Sanofi's Bioverativ, Sobi, CSL Behring and Grifols that also have made contributions to the World Hemophilia Federation (WHF) Humanitarian Aid Program, which said it helped more than 16,000 patients in 60 countries in 2017.
OTCQX: RHHBY) today announced that it has joined the World Federation of Hemophilia (WFH) Humanitarian Aid Program, a landmark initiative leading the effort to change the lack of access to care and treatment for people with inherited bleeding disorders in developing countries. Together with Chugai and Genentech, members of the Roche Group, Roche`s commitment to the WFH Program consists of a donation of Hemlibra® (emicizumab), a prophylactic treatment for haemophilia A, and funding to deliver the WFH Program`s integrated care development training to ensure that local infrastructure and medical expertise are available to optimise and appropriately use the donated Hemlibra.
2018 was a banner year for the OTC Markets in terms of dollar trading volume. According to the company, total dollar volume on the market was $375.2 billion in 2018. The marijuana sector alone accounted for $25 billion in volume last year, about 7 percent of all volume on the OTC Markets.
Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...
Swiss drugmaker Roche aims to broaden the use of its Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin. Roche said on Tuesday it had applied for U.S. Food and Drug Administration approval for Kadcyla, a five-year-old drug, for post-surgical use in women with a form of early stage breast cancer who still show signs of disease after treatment with Herceptin and chemotherapy.
Roche`s application is being reviewed under the US FDA`s Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy Designation for this application Basel, 05 ...
DoubleLine Capital CEO Jeffrey Gundlach shares his thoughts on market risks, the possibility of a recession, Fed policy and the 2020 election. He speaks exclusively with Yahoo Finance's Julia La Roche, Jen Rogers, Myles Udland and Andy Serwer.
Aurora Cannabis reported earnings for its second quarter. The company says it accounted for about 20% of all consumer sales across Canada for the quarter. Yahoo Finance's Jackie DeAngelis and Julia La Roche discuss.
Is it time to say goodbye to the travel selfie? Yahoo Finance's Zack Guzman & Julia La Roche, along with Frank CEO & Founder Charlie Javice, discuss with Flytographer CEO & Founder Nicole Smith.
Yahoo Finance's Zack Guzman and Julia La Roche discuss one countries basic income experiment with Charlie Javice, Frank founder and CEO.